RxDoctor Payments Data

Jennifer Levine

Psychiatric/Mental Health · Neptune, NJNPI 1013935790

Payments from drug & device makers

$3,464in general payments, 2019–2025

Across 142 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$859
  • AbbVie$635
  • Teva Pharmaceuticals USA, Inc.$516
  • Otsuka America Pharmaceutical, Inc.$292
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$258
  • Neurocrine Biosciences, Inc.$177
  • plus $728 from 12 others

What the payments were for

  • Food & beverage$3,30295%
  • Education$1625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,464 in reported general payments places this provider in the 85th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$27,139
Medicare patients
126
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate117$334,320
Abilify MaintenaAripiprazole31$77,214
Clozapine122$12,714
Ziprasidone Hcl59$9,577
Paliperidone ErPaliperidone27$8,551
Aripiprazole117$4,591
Lurasidone Hcl16$4,394
Olanzapine159$3,807
Fluoxetine Hcl316$3,625
Divalproex Sodium ErDivalproex Sodium73$3,197
Quetiapine Fumarate116$3,031
Bupropion XlBupropion Hcl73$2,710
Quetiapine Fumarate ErQuetiapine Fumarate15$2,501
Trazodone Hcl217$2,355
Divalproex Sodium68$2,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$859$334,320117 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$292$77,21431 claims
Lilly USA, LLCOlanzapine$40$3,807159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →